Trials
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Current Trials

Condition Name Sponsor
Follicular Lymphoma Idelalisib for Treatment of Follicular Lymphoma Gilead Sciences
Solid Tumors STARTRK-2 Ignyta, Inc.
Prostate Cancer Prostate Cancer: TRUMPET Astellas Scientific & Medical Affairs, Inc.
Observational Miraca Registry of Hematopoietic Diseases Miraca Life Science
Observational CARIS Molecular Intelligence Registry Caris Life Sciences, Inc.
Non-Small Cell Lung Cancer Inivata Liquid Biopsy Inivata, Ltd.
Non-Small Cell Lung Cancer TR(ACE) Assay Clinical Specimen Study Biological Dynamics
Pancreatic Cancer Artist 1 Pancreatic Cancer ARMO Biosciences
Multiple Myeloma Multiple Myeloma Melflufen Oncopeptides AB
Breast Cancer CONTESSA: Tesetaxel for HER2(-) Metastatic Breast Cancer Odonate Therapeutics, LLC
Breast Cancer CONTESSA-2: Tesetaxel Plus Capecitabine Odonate Therapeutics, Inc.
Non-Small Cell Lung Cancer Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer Spectrum Pharmaceuticals, Inc.
Small Cell Lung Cancer Second Line Irinotecan Versus Topotecan IPSEN Bioscience, Inc.
Hereditary Hemochromatosis Human Hepcidin for Patients Prescribed Therapeutic Phlebotomy La Jolla Pharmaceutical Company
Essential Thrombocythemia Ruxolitinib Versus Anagrelide in Patients Resistant or Intolerant to Hydroxyurea Incyte Corporation
Breast Cancer Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax George E. Peoples, Cancer Insight, LLC
Breast Cancer Ribociclib and Letrozole in HR Positive, HER2 Negative Disease Novartis Pharmaceuticals
Sample Collection SeraTrials Seratrials
Sample Collection MT Group MT Group, Inc
Observational Study informCLL Registry Study for Chronic Lymphocytic Leukemia Pharmacyclics LLC.
Observational Study Registry for Patients With Hodgkin's Lymphoma Bristol-Myers Squibb
Observational Study MOST Myelofibrosis and Essential Thrombocythemia Registry Incyte Corporation
Observational Study Palbociclib in Real World Practice Breast Cancer Registry Pfizer
Renal Cell Carcinoma CANTATA: CB-839 and Cabozanitib versus Cabozanitib and Placebo Calithera Biosciences, Inc
Breast Cancer Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Disease Cancer Insight, LLC
Prostate Cancer SM88 in Patients with Prostate Cancer Tyme, Inc
Pancreatic Cancer SM88 in Patients with Previously Treated Metastatic Disease Tyme, Inc
Indolent Non-Hodgkin's Lymphoma Copanlisib with standard immunochemotherapy in relapsed iNHL Bayer HealthCare Pharmaceuticals, Inc.
Breast Cancer DS8201a in HER2+ Patients Previously Treated with Trastuzumab and a Taxane Daiichi Sankyo, Inc.
Breast Cancer ASCENT: Sacituzumab Govitecan in Triple Negative Breast Cancer Immunomedics, Inc.
Prostate Cancer ProSTAR: CPI-1205 in Metastatic Castration Resistant Prostate Cancer Constellation Pharmaceuticals, Inc.
Triple Negative Breast Cancer VIOLETTE: A Study of Olaparib in Triple Negative Breast Cancer AstraZeneca
Breast Cancer DS8201a in HER2+ Patients Previously Treated with T-DM1 Daiichi Sankyo, Inc.
Prostate Cancer KPG-121 in Castration Resistant Prostate Cancer Kangpu Biopharmaceuticals, Ltd.
RET Mutated Solid Tumors LIBRETTO: Loxo-292 in RET Mutated Solid Tumors Loxo Oncology, Inc.
Paroxysmal Nocturnal Hemoblobinuria PEGASUS: APL-2 for PNH Patients Being Treated with Eculizumab Apellis Pharmaceuticals, Inc.
Diffuse Large B-Cell Lymphoma Loncastuximab Tesirine in Previously Treated Diffuse Lare B-Cell Lymphoma ADC Therapeutics
Non-Small Cell Lung Cancer Anamorelin for Weigh Loss or Anorexia Associated with Cancer Treatment Helsinn Healthcare SA
Oropharynx or Oral Cavity ROMAN: GC4419 for Radiation Induced Oral Mucositis Galera Therapeutics, Inc.
Triple Negative Breast Cancer CONTESSA Trio: Tesetaxel Plus Immunotherapy Odonate Therapeutics, Inc.
Multiple Conditions SEERPRO Blood Sample Collection Seer, Inc.
Advanced Solid Tumors Cabozantinib plus Atezolizumab in Multiple Tumor Types Exelixis
Prostate Cancer Proxalutamide in Patients Previously Treated with Abiaterone or Enzalutamide Suzhou Kintor Pharmaceutical Inc.